Cargando…
COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis
Up‐to‐date information on coronavirus disease 2019 (COVID‐19) outcomes and risk factors in haematopoietic cell transplantation (HCT) recipients is required to inform on decisions about cancer treatment and COVID‐19 mitigation strategies. We performed a meta‐analysis to address this knowledge gap. Al...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350043/ https://www.ncbi.nlm.nih.gov/pubmed/35941880 http://dx.doi.org/10.1002/jha2.465 |
_version_ | 1784762174992809984 |
---|---|
author | Lim, Yeong Jer Khan, Umair Karpha, Indrani Ross, Andrew Saif, Muhammad Remberger, Mats Kalakonda, Nagesh Pettitt, Andrew R. Floisand, Yngvar |
author_facet | Lim, Yeong Jer Khan, Umair Karpha, Indrani Ross, Andrew Saif, Muhammad Remberger, Mats Kalakonda, Nagesh Pettitt, Andrew R. Floisand, Yngvar |
author_sort | Lim, Yeong Jer |
collection | PubMed |
description | Up‐to‐date information on coronavirus disease 2019 (COVID‐19) outcomes and risk factors in haematopoietic cell transplantation (HCT) recipients is required to inform on decisions about cancer treatment and COVID‐19 mitigation strategies. We performed a meta‐analysis to address this knowledge gap. All studies with at least five patients who reported COVID‐19‐related deaths in HCT recipients were included. The primary outcome was COVID‐19‐related death. Secondary outcomes were COVID‐19‐related mechanical ventilation (MV) and intensive care unit (ITU) admission. The cumulative COVID‐19‐related death rate among HCT recipients was 21% (95% confidence interval [CI] 18%–24%), while MV and ITU admission rates were 14% (95% CI 11%–17%) and 18% (95% CI 14%–22%), respectively. Subgroup analysis showed higher death rates in patients who developed COVID‐19 within 12 months of HCT (risk ratio [RR] 1.82, 95% CI 1.09–3.03), within 6 months of receiving immunosuppressant drugs (RR 2.11, 95% CI 1.38–3.20) or in the context of active graft‐versus‐host disease (RR 2.38, 95% CI 1.10–5.16). Our findings support the idea that HCT should remain an integral part of cancer treatment during the COVID‐19 pandemic but also highlight the need to prioritise preventative measures in those patients who are at increased risk of adverse COVID‐19 outcomes. |
format | Online Article Text |
id | pubmed-9350043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93500432022-08-04 COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis Lim, Yeong Jer Khan, Umair Karpha, Indrani Ross, Andrew Saif, Muhammad Remberger, Mats Kalakonda, Nagesh Pettitt, Andrew R. Floisand, Yngvar EJHaem Cell Therapy/Stem Cell Transplantation Up‐to‐date information on coronavirus disease 2019 (COVID‐19) outcomes and risk factors in haematopoietic cell transplantation (HCT) recipients is required to inform on decisions about cancer treatment and COVID‐19 mitigation strategies. We performed a meta‐analysis to address this knowledge gap. All studies with at least five patients who reported COVID‐19‐related deaths in HCT recipients were included. The primary outcome was COVID‐19‐related death. Secondary outcomes were COVID‐19‐related mechanical ventilation (MV) and intensive care unit (ITU) admission. The cumulative COVID‐19‐related death rate among HCT recipients was 21% (95% confidence interval [CI] 18%–24%), while MV and ITU admission rates were 14% (95% CI 11%–17%) and 18% (95% CI 14%–22%), respectively. Subgroup analysis showed higher death rates in patients who developed COVID‐19 within 12 months of HCT (risk ratio [RR] 1.82, 95% CI 1.09–3.03), within 6 months of receiving immunosuppressant drugs (RR 2.11, 95% CI 1.38–3.20) or in the context of active graft‐versus‐host disease (RR 2.38, 95% CI 1.10–5.16). Our findings support the idea that HCT should remain an integral part of cancer treatment during the COVID‐19 pandemic but also highlight the need to prioritise preventative measures in those patients who are at increased risk of adverse COVID‐19 outcomes. John Wiley and Sons Inc. 2022-06-14 /pmc/articles/PMC9350043/ /pubmed/35941880 http://dx.doi.org/10.1002/jha2.465 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cell Therapy/Stem Cell Transplantation Lim, Yeong Jer Khan, Umair Karpha, Indrani Ross, Andrew Saif, Muhammad Remberger, Mats Kalakonda, Nagesh Pettitt, Andrew R. Floisand, Yngvar COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis |
title | COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis |
title_full | COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis |
title_fullStr | COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis |
title_full_unstemmed | COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis |
title_short | COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis |
title_sort | covid‐19 outcomes in haematopoietic cell transplant recipients: a systematic review and meta‐analysis |
topic | Cell Therapy/Stem Cell Transplantation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350043/ https://www.ncbi.nlm.nih.gov/pubmed/35941880 http://dx.doi.org/10.1002/jha2.465 |
work_keys_str_mv | AT limyeongjer covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis AT khanumair covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis AT karphaindrani covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis AT rossandrew covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis AT saifmuhammad covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis AT rembergermats covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis AT kalakondanagesh covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis AT pettittandrewr covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis AT floisandyngvar covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis |